ARK has been one of the biggest stories in the ETF world lately. With an incredible asset growth of more than 1000%, ARK is now a top 10 ETF issuer.

While there have been winners in many corners of the space, here are five sector ETFs that have been outperforming this year.

Small caps beat the major indexes, but the sectors that did even better are clean energy, regional banking, cannabis, and biotech.

There are several companies working on helping you achieve a greater longevity, which are involved in targeting human aging and degenerative diseases. Here are several that are close to longevity pure plays.

Merger and acquisition activities have heated up in recent months and the niche spaces are in the limelight. After the telemedicine industry, gene therapy stocks jumped on the bandwagon.

While there have been winners in many corners of the space, we highlight four sector ETFs that have doubled so far this year:

Biotech ETFs have done quite well this year as many pharma and biotech companies are working on coronavirus vaccines, therapeutics, and testing.

The coronavirus outbreak seems to get severe in the United States as more than 3.3 million cases have been recorded with a death toll of at least 135,205.

The race to introduce vaccine and treatment for coronavirus is opening up opportunities, making the biotech sector a prospective space for investments. Therefore, we discuss a few ETFs that provide exposure to the biotech sector:

Given rising spending on drugs and healthcare all over the world, investors should tap the opportune moment by investing in the biotech sector.

The scramble to bring a coronavirus vaccine to market is lifting the health care sector this year as a slew of biotechnology and other, more nuanced exchange-traded funds targeting the group are delivering impressive returns.

It appears that growing demand for personalized medicine, solid investments and higher R&D activities can make genomics the next big thing in the investing space. We highlight a host of ETFs that investors can keep tabs on.

The rush is on to develop vaccines and therapies.

Biotech ETFs are surging with many hitting new 52-week highs lately.

We have seen very strong M&A activity in the biotech space of late and the trend is expected to continue as big pharmaceutical companies are trying to gain an edge in the increasingly competitive cancer treatment market.

These funds focus exclusively on U.S. equities and deserve the attention of investors seeking a domestic tilt to their portfolio ahead of the Jul 4 holiday.